Avecho Biotechnology Limited (ASX: AVE) has announced it will continue recruiting participants for its Phase III insomnia trial following a positive interim analysis of its TPM®-enhanced cannabidiol (CBD) capsule. This analysis marks a significant milestone for the program, lowering clinical development risks and paving the way for completion of the trial.
Read More
The independent Data Monitoring Board (DMB), composed of experts in sleep medicine, clinical safety, and biostatistics, reviewed the unblinded interim data from the clinical trial. They unanimously recommended continuing the study to its full enrolment goal of 519 participants. This recommendation confirms that the study met the criteria set out in its protocol to advance past the interim analysis and recruit a second cohort of patients.
Avecho CEO Dr. Paul Gavin stated that this development is a crucial milestone for the company and aligns with their trial objectives. He emphasized that the trial's design—featuring two independent endpoints and rigorous controls—was instrumental in demonstrating the product’s efficacy. Dr. Gavin noted, "Although we remain blinded and the study is not complete, so final outcomes cannot be determined until then, we are more confident than ever that our CBD capsule works as a treatment for insomnia."
The interim analysis included data from 244 participants randomized into three groups receiving nightly doses of either 150mg CBD, 75mg CBD, or a placebo over an eight-week period. Additionally, safety data indicated no serious adverse events recorded among the participants, supporting the product's tolerability, which is crucial for its commercial rationale.
Dr. Gavin highlighted the shift in focus towards commercialization, advocating for the CBD capsule’s potential benefits compared to current sleep medications, which often have limitations like next-day impairment and overdose risks that cannabidiol does not present.